Log In
BCIQ
Print this Print this
 

givosiran (ALN-AS1)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1)
Molecular Target Aminolevulinate synthase-1 (ALAS-1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationPorphyria
Indication DetailsTreat acute hepatic porphyrias; Treat acute intermittent porphyria (AIP)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/13/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today